ArticleInternational journal of clinical and experimental pathology2014
Down-expression of F box only protein 8 correlates with tumor grade and poor prognosis in human glioma.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- FBX8 promotes metastatic dormancy of colorectal cancer in liver.Cell death & disease · 2020Article
- FBX8 degrades GSTP1 through ubiquitination to suppress colorectal cancer progression.Cell death & disease · 2019Article
- Posttranscriptional Repression of FBXW7 and FBXO8 by microRNA-223 Regulates Ubiquitin-dependent Proteostasis in Periodontal Disease.Contemporary clinical dentistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
F box only protein 8 (FBX8) is a novel component of F-box proteins which involved in the ubiquitin-dependent proteolytic pathway. Recent studies have revealed that FBX8 was unregulated in tumor cells and was closely associated with tumor progression and metastasis of other cancer, but little research has been done yet to test its usefulness as a prognostic marker in human glioma. In the present study, we investigated the expression of FBX8 in glioma tissues using immunohistochemical analysis and evaluated its prognostic significance in glioma. We found that 44/77 (57.14%) gilomas had positive expression of FBX8, while 65/77 (84.42%) normal brain tissue had positive expression of FBX8. The expression level of FBX8 was remarkably down-regulated in glioma tissues compared with normal brain tissues (P < 0.001). The down-expression of FBX8 in tumor cells was strongly correlated with tumor grade of patients with glioma (P < 0.05). Patients with lower expression of FBX8 protein had shorter overall survival time than those with higher level expression of FBX8 (P < 0.05). Multivariate analysis showed that FBX8 down-expression was an independent prognostic indicator for glioma patient's survival. Our results suggest that a potential application of FBX8 in prognosis prediction and therapeutic application in glioma.
Indexed as
Identifiers
25550853PMC4270539W2286981176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.